Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update

About this update from Novocure Limited

[{"type":"text","content":"\nFull year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019\n\nNovocure to present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021\n\nFourth quarter and full year 2020 financial results to be reported Thursday, Feb. 25, 2021\n\n ST. HELIER, Jersey--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. Novocure plans to discuss these results with investors at the 39th Annual J.P. Morgan Virtual Healthcare Conference. Novocure also plans to highlight key clinical and product development programs.\n\n\n\nFourth quarter and full year 2020 highlights include:\n\n\n\n\n\n \n\n\n\n\n\n\nThree months ended\nDecember 31,\n\n\n\n \n\n\n\nTwelve months ended\nDecember 31,\n\n\n\n \n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n2020\n\n\n\n \n\n\n\n \n\n\n\n2019\n\n\n\n \n\n\n\n% Change\n\n\n\n \n\n\n\n \n\n\n\n2020\n\n\n\n \n\n\n\n \n\n\n\n2019\n\n\n\n \n\n\n\n% Change\n\n\n\n \n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n(unaudited)\n\n\n\n \n\n\n\n \n\n\n\n(audited)\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n(unaudited)\n\n\n\n \n\n\n\n \n\n\n\n(audited)\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nFinancial, in millions\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nNet revenues(1)\n\n\n\n\n\n\n$\n\n\n\n144.0\n\n\n\n \n\n\n\n$\n\n\n\n99.2\n\n\n\n \n\n\n\n45%\n\n\n\n \n\n\n\n$\n\n\n\n494.4\n\n\n\n \n\n\n\n$\n\n\n\n351.3\n\n\n\n \n\n\n\n41%\n\n\n\n \n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nCash, cash equivalents and\nshort-term investments at period end(1)\n\n\n\n\n\n\n$\n\n\n\n842.6\n\n\n\n \n\n\n\n$\n\n\n\n326.1\n\n\n\n \n\n\n\n158%\n\n\n\n \n\n\n\n$\n\n\n\n842.6\n\n\n\n \n\n\n\n$\n\n\n\n326.1\n\n\n\n \n\n\n\n158%\n\n\n\n \n\n\n\n\n\nNon-financial\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nActive patients at period end(2)\n\n\n\n\n\n\n \n\n\n\n3,411\n\n\n\n \n\n\n\n \n\n...

More updates from Novocure Limited